Internal Med Medical News about Acute gout

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cochrane Musculoskeletal Group review: Acute gout
The Journal of Family Practice, 07/02/09

Winzenberg T et al. - Gout afflicts about 2% of men over age 30 and women over age 50 and its prevalence appears to be increasing. Options for treating acute gout include nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and intra-articular and systemic corticosteroids. Choosing among them can be challenging, however, because the evidence that one or another of these options yields real benefit is of varying strength. Using NSAIDs can be problematic with increasing age, as comorbidities like gastrointestinal (GI) bleeding, renal failure, heart failure, and cardiovascular risk increase and anticoagulant therapy is more likely to be in use. That’s where the kind of systematic reviews Cochrane Musculoskeletal Group (CMSG) performs can be of real help.

Test your skills with 2 cases
All 22 participants who took colchicine developed diarrhea or vomiting within 24 hours of initiating therapy
One RCT found that oral prednisolone 35 mg daily and naproxen 500 mg twice daily were clinically equivalent
NSAIDs are a reasonable first option, provided there are no contraindications

<< Previous
Migraine treatment "tweak" could reduce office visits

Next >>
Systemic chemotherapy for bladder cancer